Axys Pharmaceuticals Names Michael J. Green, Ph.D. Vice President, Medicinal Chemistry.Business Editors, Health/Medical Writers SOUTH SAN FRANCISCO South San Francisco, city (1990 pop. 54,312), San Mateo co., W Calif.; inc. 1908. South San Francisco has several industrial parks; its manufactures include medical supplies and equipment, foods, paint, paper products, consumer goods, and clothing. , Calif.--(BW HealthWire)--Sept. 13, 2000 Axys Pharmaceuticals, Inc. (Nasdaq:AXPH) today named Michael John Green, Ph.D. vice president of medicinal chemistry Medicinal or pharmaceutical chemistry is a scientific discipline at the intersection of chemistry and pharmacology involved with designing, synthesizing and developing pharmaceutical drugs. , reporting to Michael C. Venuti, Ph.D., senior vice president of research and preclinical development and chief technical officer. Dr. Green will be responsible for directing drug discovery medicinal chemistry, managing the 60 chemists currently on staff that will occupy Axys' new medicinal chemistry facility, now under construction and scheduled for completion in mid-2001. Dr. Green joins Axys from Trega Biosciences where he was most recently vice president of the company's Drug Discovery Division. For 25 years, from 1971-1996, Dr. Green worked at the Schering-Plough Research Institute, specializing in the discovery of inflammatory drugs, and participated on the team that discovered the blockbuster allergy drug, Claritin(R). Before leaving Schering-Plough for Trega, Dr. Green was Director, Chemical Research -- Cardiovascular and CNS See Continuous net settlement. CNS See continuous net settlement (CNS). , and was responsible for the chemistry of new drug discovery, as well as the supervision of a 50-person scientific team. Before joining Schering-Plough, Dr. Green worked at the Brookhaven National Laboratory Brookhaven National Laboratory, scientific research center, at Upton (town of Brookhaven), Long Island, N.Y. It was founded in 1947 by Associated Universities, a management corporation sponsored by nine eastern U.S. universities. and the Ben May Laboratory for Cancer Research at the University of Chicago. Dr. Green received his Ph.D. in Organic Chemistry and his B.Sc. from the University of Sheffield The University of Sheffield is a research university, located in Sheffield in South Yorkshire, England. Reputation Sheffield was the Sunday Times University of the Year in 2001 and has consistently appeared as their top 20 institutions. , England, in 1967. His doctoral research was conducted in the laboratory of Dr. Neville Jones. A member of the American Chemical Society The American Chemical Society (ACS) is a learned society (professional association) based in the United States that supports scientific inquiry in the field of chemistry. Founded in 1876 at New York University, the ACS currently has over 160,000 members at all degree-levels and in , and a fellow of the Royal Society Fellow of the Royal Society is an honour accorded to distinguished scientists and a category of membership of the Royal Society. Fellows are entitled to put the letters FRS after their name. Up to 44 new fellows are elected each year by ballot of the existing fellows. of Chemistry as a Life Science Symposium Committee Member and Chairman in 1986, Dr. Green is author or co-author of more than 40 peer-reviewed publications, book chapters, and review articles. Additionally, he is the inventor or co-inventor of 33 issued United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. patents. According to Dr. Venuti, "Mike Green has proven himself an able leader in science and in the strategic management of scientific organizations. With over 25 years of experience at Schering Plough and his more recent work at Trega, he brings to Axys significant expertise in discovering drugs that meshes directly with Axys' existing strengths in medicinal chemistry. In addition, Dr. Green has extensive experience in managing collaborative drug discovery research, having worked with Ono, Chugai, Biogen, Parke-Davis and Novartis, among others. As Axys further expands its oncology product pipeline and advances its existing collaborative research programs with Merck, Aventis, and Bayer, we expect Mike's experience to make a substantial contribution to our ongoing partnerships as well as our efforts to develop a proprietary oncology pipeline leading to a line of commercial oncology products." Axys Pharmaceuticals, Inc. is an integrated small molecule drug discovery and development company. Axys has a broad pipeline of products for chronic therapeutic applications that are partnered with world-class pharmaceutical companies and a proprietary product portfolio in oncology. Axys is also building shareholder value through affiliated businesses that leverage the Axys technologies in order to provide capital for Axys' drug discovery and development programs. In addition to a minority interest in Discovery Partners International (Nasdaq:DPII DPII Discovery Partners International, Inc. ) resulting from the merger of its combinatorial chemistry business Axys Advanced Technologies, with DPII and the subsequent IPO (Initial Public Offering) The first time a company offers shares of stock to the public. While not a computer term per se, many founders, employees and insiders of computer companies have found this acronym more exciting than any tech term they ever heard. of DPII, Axys' technology leveraging businesses are: PPGx, a majority-owned pharmacogenomics company, and Akkadix Corporation, an agricultural biotechnology company. For more information about Axys Pharmaceuticals, Inc., please visit the company's website at http://www.axyspharm.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion